Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | ACLY | P53396 | 1/20 | 0.51 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3809703 | 0.92 | NPSR1 (0.56) | NPSR1KDM4ERXFP1ACLYMMP2 | |
| SCHEMBL2158247 | 0.89 | NPSR1 (0.60) | NPSR1KDM4EACLY | |
| SCHEMBL2158020 | 0.89 | ACLY (0.65) | NPSR1ACLYMMP2 | |
| SCHEMBL2158415 | 0.85 | PTPN1 (0.51) | NPSR1KDM4ERXFP1ACLYMMP2 | |
| SCHEMBL2157967 | 0.82 | NPSR1 (0.84) | NPSR1KDM4ERXFP1ACLY | |
| SCHEMBL2158232 | 0.81 | NPSR1 (0.61) | NPSR1KDM4ERXFP1ACLY | |
| SCHEMBL3809704 | 0.78 | MMP2 (0.49) | NPSR1KDM4ERXFP1METAP2MMP2 | |
| SCHEMBL2255621 | 0.77 | NPSR1 (0.57) | NPSR1KDM4ERXFP1ACLY | |
| SCHEMBL2158139 | 0.76 | NPSR1 (0.83) | NPSR1KDM4ERXFP1ACLY | |
| SCHEMBL2157980 | 0.76 | NPSR1 (0.61) | NPSR1KDM4ERXFP1ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123242-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123242-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | HAVCR2, ZC3HAV1, MAVS | NPSR1 2975/4885KDM4E 3220/4885RXFP1 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.